Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1867066 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $6.81 · Day +2.25% · Mkt cap $163M · 1Y −3.7% · Off 52W high −28.7% · Vol (1Y) 63.1% Price2023-08-21 → 2026-08-19 DERM close: $1.97 on 2023-08-21 to $6.81 on 2026-08-19. Split-adj closes · 240 of 2,061 · price returnⓘ At a glance | Short interest11.7% of sh out | | Days to cover20.5d | | 13F net flow (QoQ)+4.30% | | Top-10 13F concentration76.2% | | Next report (est.)2026-11-11 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$68.2M | | Earnings (TTM)-$6.1M | | ROE−44.0% | | Net margin−18.5% | | ROIC−22.4% | | Debt / equity0.79× | | Sales growth 3Y−5.7% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−11.7% | | 1Y−3.7% | | 3Y+245.7% | | 5Y+39.0% | | 10Y−78.7% | | Since incept. (ann.)−13.7% |
Total return · from 2016-07-11ⓘ Risk | Ann. volatility (1Y)63.1% | | Ann. volatility (3Y)79.2% | | Sharpe (1Y)0.29 | | Sharpe (3Y)0.90 | | Max drawdown (1Y)−52.6% | | Max drawdown (3Y)−63.3% | | Beta (3Y vs SPY)1.00 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| WASATCH ADVISORS LP | 2.1M | $10M | 8.71% | +62.1% | | TANG CAPITAL MANAGEMENT LLC | 1.6M | $8M | 6.57% | −13.2% | | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $5M | 4.42% | new | | BlackRock, Inc. | 972,862 | $5M | 3.97% | +35.2% | | Opaleye Management Inc. | 960,000 | $5M | 3.92% | −1.5% | | J. Goldman & Co LP | 500,188 | $2M | 2.04% | −37.3% | | Pale Fire Capital SE | 481,987 | $2M | 1.97% | +8.4% | | GEODE CAPITAL MANAGEMENT, LLC | 463,202 | $2M | 1.89% | +47.5% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-12 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-12 | −$0.01 | — | $18.5M | +23.3% | | 2026-03-31 | 2026-05-13 | −$0.08 | — | $16.0M | +21.5% | | 2025-12-31 | 2026-03-25 | — | — | $16.1M | +18.1% | | 2025-09-30 | 2025-11-12 | −$0.09 | — | $17.6M | +20.5% |
As-reported XBRL · next 2026-11-11 est.ⓘ Segment mixFY2025 (ended Dec 2025) Qbrexza 41% · Emrosi 24% · Accutane 21% · Foam Franchise Products Amzeeq Zilxi 10% · Other Legacy 4% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
